Celgene poaches Merck exec to head clinical development

US biotech Celgene (Nasdaq: CELG) has appointed Dr Alise Reicin as president, global clinical development, reporting to Mark Alles, chairman and chief executive, effective November 1, 2018.

In this role, Dr Reicin will be responsible for all aspects of mid- to late-stage clinical development across Celgene’s portfolio and will serve on the company's executive committee.

“Dr Reicin is an accomplished physician with an excellent record of developing important therapeutics for multiple cancer and inflammatory indications,” said Mr Alles, adding: “Led by Alise, our clinical development organization will be structured to more completely align with our strategy and mission to discover, develop and commercialize innovative therapies for patients with unmet need. She joins Dr Rupert Vessey, president, research & early Development, and Dr Jay Backstrom, chief medical officer, as we deliver the potential of our deep and broad pipeline.”